Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Comment by Alba1314on Jun 21, 2018 9:32am
87 Views
Post# 28204555

RE:RE:RE:Targeted Markets iCo-007 - Diabetes-Related Blindness ~$3B+.

RE:RE:RE:Targeted Markets iCo-007 - Diabetes-Related Blindness ~$3B+.Not bashing the stock, as I own 100K shares, but Andrew Rae buying $20,000 worth of shares, to me, means nothing. If he really knew something, then $20K is chump change. Wouldnt you be remortgaging your home if you "knew something"?

The $32 milliom is still a ways off and is still only a possibility though I agree it can't be dismissed. But there's still a few more years of studies to be completeted. Correct me if I'm wrong, but if the drug doesnt go to market, then the $32M never happens.

Completing recruitment for the oral Amp B study is a plus but we still need to see more positive results. 

I dont see this moving that much higher. Too much speculation at this point. Would love to be wrong!
<< Previous
Bullboard Posts
Next >>